AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
oxymetholone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| steroids not used as glucocorticosteroids | 2033 | 434-07-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A synthetic hormone with anabolic and androgenic properties. It is used mainly in the treatment of anemias. According to the Fourth Annual Report on Carcinogens (NTP 85-002), this compound may reasonably be anticipated to be a carcinogen. (From Merck Index, 11th ed)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.25 | g | O |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 15.04 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 2 | Bocci G, Oprea TI, Benet LZ |
| S (Water solubility) | 0.01 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2B,BRAF,CAMK2D,CDK5,EIF2AK3,ERBB2,GRK2,ITK,MAPK10,MAPK7,NTRK2,PDK1,PDK2,PDK4,PRKDC,TEK | 16 | |||
| kinase-selectivity-class | EIF2AK3,GRK2 | 2 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 18, 1972 | FDA | MEDA PHARMS |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | A14AA05 | ALIMENTARY TRACT AND METABOLISM ANABOLIC AGENTS FOR SYSTEMIC USE ANABOLIC STEROIDS Androstan derivatives |
| MeSH PA | D000728 | Androgens |
| MeSH PA | D006728 | Hormones |
| MeSH PA | D045930 | Anabolic Agents |
| CHEBI has role | CHEBI:36413 | anabolic agent |
| CHEBI has role | CHEBI:50113 | androgen |
| CHEBI has role | CHEBI:75835 | anti-anaemic agent |
Related Drugs by ATC class:
A14AA Androstan derivatives 8 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hypoplastic anemia | indication | 41614006 | |
| Congenital hypoplastic anemia | indication | 88854002 | DOID:1339 |
| Aplastic anemia | indication | 306058006 | DOID:12449 |
| Hypercholesterolemia | contraindication | 13644009 | |
| Humoral hypercalcemia of malignancy | contraindication | 47709007 | |
| Chronic heart failure | contraindication | 48447003 | |
| Nephrotic syndrome | contraindication | 52254009 | DOID:1184 |
| Heart disease | contraindication | 56265001 | DOID:114 |
| Peliosis hepatis | contraindication | 58008004 | DOID:914 |
| Hepatic failure | contraindication | 59927004 | |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Arteriosclerotic vascular disease | contraindication | 72092001 | |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Neoplasm of prostate | contraindication | 126906006 | DOID:10283 |
| Liver function tests abnormal | contraindication | 166603001 | |
| Hypoalphalipoproteinemia | contraindication | 190785000 | |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Edema | contraindication | 267038008 | |
| Pregnancy, function | contraindication | 289908002 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Carcinoma of female breast | contraindication | 447782002 | |
| Breast Carcinoma in Males | contraindication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.87 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Androgen receptor | Nuclear hormone receptor | AGONIST | WOMBAT-PK | CHEMBL | |||||
| Estrogen receptor | Nuclear hormone receptor | WOMBAT-PK | |||||||
| Androgen receptor | Transcription factor | Ki | 6.86 | DRUG MATRIX |
External reference:
| ID | Source |
|---|---|
| 4018432 | VUID |
| N0000146758 | NUI |
| D00490 | KEGG_DRUG |
| 4018432 | VANDF |
| C0030072 | UMLSCUI |
| CHEBI:7864 | CHEBI |
| CHEMBL1200585 | ChEMBL_ID |
| DB06412 | DRUGBANK_ID |
| D010110 | MESH_DESCRIPTOR_UI |
| 5281034 | PUBCHEM_CID |
| 1022 | INN_ID |
| L76T0ZCA8K | UNII |
| 7813 | RXNORM |
| 5219 | MMSL |
| d04295 | MMSL |
| 001255 | NDDF |
| 126101002 | SNOMEDCT_US |
| 6116004 | SNOMEDCT_US |
| L76T0ZCA8K | INXIGHT DRUGS |
Pharmaceutical products:
None